Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis

• Status: Completed
• Trial end date: 2020-06-26
• Target enrollment: 0
• Participant gender: All

Summary

Atopic dermatitis (AD) is a chronic and recurrent inflammatory disease, prevalent between 1 and 20% in the world population, with a predominance of childhood, but which may be present in adult life. AD results from a complex interaction between genetic and environmental factors, with the presence of a defect in the skin barrier and deregulation of the immune response, culminating in an inflammatory response in the skin predominantly type 2. Disease control is based on restoring skin hydration, smoothing itching and controlling the process specific sensitizing agents such as inhalant allergens and foods that may pathogenesis of the disease. In selected patients who present IgE mediated response to inhalant allergens, allergen-specific immunotherapy can be effective. Classically, the subcutaneous route is the most used, however, sublingual immunotherapy (SLIT) has been used in increasing form. There are still few studies on the efficacy and safety of SLIT in atopic dermatitis. Therefore, the present study aims to to investigate the role of SLIT in the management of patients with AD allergic mites, through a randomized, double-blind and placebo-controlled study

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Casa Espirita Terra de Ismael
• Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Treatments: Immunologic Factors

Criteria

Inclusion Criteria:

• Diagnosis of AD according to Hanifin and Rajka criteria;

• Age greater than or equal to 3 years;

• SCORAD equal to or greater than 15 points;

• Presence of skin tests and / or specific IgE positive for Dermatophagoides pteronyssinus and / or Dermatophagoides farinae;

Exclusion Criteria:

• Pregnancy or breastfeeding;